Summary
WASHINGTON - The Supreme Court appeared likely Monday to decide an amputee's lawsuit against a drug maker based on how much federal regulators knew about an anti-nausea drug's risks in the event of a botched injection.
Several justices indicated that if the U.S. Food and Drug Administration had clear information about the risks of Wyeth Pharmaceuticals' anti-nausea drug Phenergan, and approved its warning label anyway, then Wyeth probably would prevail in its court fight against Diana Levine of Vermont.See the full content of this document
Extract
Court Weighs Amputee's Case, Limits On Drug Suits
But there was considerable skepticism among the justices - and disagreement between the opposing lawyers - that the FDA had a clear picture of the disastr...
See the full content of this document
Sponsored links
